Biomarin Pharmaceutical - Registered Shares Profit Margin

Biomarin Pharmaceutical - Registered Shares posts a profit margin of 2.14% as of June 2026. That compares with 14.48% in the prior-year period — down 85.2% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Biomarin Pharmaceutical - Registered Shares's profit margin was 14.48%. The latest reading is 2.14% — a 85.2% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Biomarin Pharmaceutical - Registered Shares's 2.14% is lower that level. That is roughly 84.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Biomarin Pharmaceutical - Registered Shares's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 2.14% as of June 2026; use YoY and peer views to separate noise from signal.

Context for BMRN's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Biomarin Pharmaceutical - Registered Shares's other metric pages and overview cover the third.